101
-1.94%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PRISM BioLab Co
Its shares trade on Tokyo Stock Exchange under the ticker 206A.T. It has been listed since 2 July 2024. In the fiscal year to 30 September 2025, it reported revenue of ¥677.3m and a net loss of ¥833.7m. At that date it held total assets of ¥3.09bn and shareholders' equity of ¥2.71bn.
PRISM BioLab Co Ltd is a JP-based company operating in Pharmaceuticals industry. The company is headquartered in Fujisawa-Shi, Kanagawa-Ken. The company went IPO on 2024-07-02. PRISM BioLab Co Ltd is a Japan-based company mainly engaged in the drug discovery business. The firm operates through Japan drug discovery business segment. The firm builds a new drug discovery platform and develops new drugs. The firm conducts research and development of pharmaceuticals using their owned drug discovery platform technology PepMetics technology. There are two business models. The in-house development business is engaged in the select of drug discovery targets and creates programs in-house. The joint development business creates programs using their owned technology to target drug discovery targets for pharmaceutical companies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Jul 2024
- Employees
- 17
- Website
- prismbiolab.com ↗
Leadership
Pay as last reported
- Mr. Dai TakeharaPresident, Chief Executive Officer, Representative Director
- Mr. Michihiro MaedaChief Financial Officer, Director in Administration Unit, Director
- Dr. Tetsuya TomaChief Technology Officer
- Dr. Hyi-man ParkDirector of Research and Development, Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PRISM BioLab operates a proprietary PepMetics drug discovery platform for new drug development.
- The company employs 17 full-time staff dedicated to pharmaceutical research and development.
- PRISM BioLab maintains a Japan-based segment focused on domestic drug discovery activities.
Weaknesses
- The firm has a small workforce of only 17 employees for operations.
- PRISM BioLab is a newly listed entity on the market since July 2024.
- The company relies heavily on its owned technology for all drug discovery programs.
Opportunities
- PRISM BioLab can expand its joint development business with external pharmaceutical companies.
- The firm may grow its in-house development programs using PepMetics technology.
- PRISM BioLab can leverage its platform to select new drug discovery targets.
Threats
- PRISM BioLab faces competition in the Japanese pharmaceuticals industry sector.
- The company depends on the success of its specific drug discovery platform.
- PRISM BioLab must sustain its 17-employee structure for ongoing research activities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.